A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL).
David L. Porter
Research Funding - Novartis
Noelle V. Frey
No relevant relationships to disclose
Alison W. Loren
No relevant relationships to disclose
Bruce Levine
Employment or Leadership Position - University of Pennsylvania
Research Funding - Novartis
Michael Kalos
Employment or Leadership Position - University of Pennsylvania
Holly McConville
No relevant relationships to disclose
Joan Gilmore
No relevant relationships to disclose
Anne Chew
No relevant relationships to disclose
Angela Shen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Charlene So
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Michele Sharr
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Patricia Ann Wood
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Carl H. June
Honoraria - Novartis
Research Funding - Novartis